We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Magneto-plasmonic Nanoparticle Platform for Capture, Separation and Enumeration of Rare Cells

Video   May 27, 2014

 

Abstract

Detection of disseminated tumor cells or tumor biomarkers in human fluids such as blood, urine, and saliva can provide an accessible tool for cancer detection and therapy monitoring. In particular, accurate quantitation of cancer cells in the bloodstream can help to determine prognosis and monitor the effectiveness of cancer therapy. However, the challenge of detecting circulating tumor cells (CTCs) is their rare occurrence, estimated as one to few CTCs among millions of leukocytes and billions of erythrocytes. Here we address this challenging problem by developing nanoparticle probes with multiple functionalities.

 
 
 
Advertisement
 

Recommended Videos

DNA in Urine for Liquid Biopsy of Cancer

Video

Urinalysis has long been a staple of physical exams to detect and manage a number of diseases and disorders, but not cancer. What if it were that easy, though, and cancer was detected in its very earliest stages when the disease responds more favorably to treatment and improved outcomes are more likely?

WATCH NOW

COVID, One Year Later: What Do We Know Now?

Video

ACS Reactions catch up with experts they talked to at the start of the pandemic and ask, "what do we know now that we didn’t back then?"

WATCH NOW

Your COVID-19 Vaccine Questions Answered

Video

Millions of people are now being immunized with the new Pfizer/BioNTech and Moderna mRNA vaccines. Are they effective? Are they safe? Infectious disease and global health expert Carlos del Rio, MD, of Emory University answers your questions.

WATCH NOW

 

Like what you just watched? You can find similar content on the communities below.

Applied Sciences Cancer Research Drug Discovery Proteomics & Metabolomics Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE